Understanding the SARS-Cov2 epidemic is a major public health issue, both in the community and in the hospital sector. Because of their central position in the management of patients infected with COVID-19, hospital staff may be considered at high risk of infection. The development of serological tests makes it possible to reliably document a contamination, symptomatic or not, that is more than 3 weeks old. These tests, combined with clinical questioning of the symptoms, make it possible to determine the proportion of asymptomatic infections whose impact in the transmission of this disease appears to be major. The duration of the presence of the antibodies that are hoped to neutralize after infection with CoV2-SARS remains uncertain. Documenting the evolution of antibody levels and their monitoring in a population at high risk of re-exposure to CoV2-SARS is a major issue in understanding this disease and in assessing the risk of infection among healthcare workers.
This is a multi-center, prospective, interventional, low-risk, low-constraint, biological
collection study to assess the exposure of health care workers to COVID-19.
Three blood samples will be taken at day 1, month 3 and month 6. The blood samples will be
stored in a serum biological collection. A prospective data collection will be set up at the
level of symptoms and co-morbidities at each collection at D1, M3 and M6.
In the event of the appearance of symptoms between samples, a self-questionnaire will be
completed by the participating personnel as well as an invitation to screening by RT-PCR SARS
Cov2 according to standard practices in force at the national level as well as an additional
serological test.
Diagnostic Test: Diagnostic test Covid-19
Three blood samples will be taken at day 1, month 3 and month 6 A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.
Inclusion Criteria:
- Staff on duty in the health facility
- Eligible to be drawn
- Beneficiary subject affiliated or entitled to a social security scheme
Exclusion Criteria:
- Minor patient
- Refusal to participate
- Patient under guardianship
- Patient under guardianship
CH Roubaix
Roubaix, France
CH Tourcoing
Tourcoing, France
CH Wasquehal
Wasquehal, France
CH Wattrelos
Wattrelos, France
PATOZ Pierre, PharmD, Principal Investigator
CH Tourcoing